Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Last trade$2.97
Day change+$0.06 (+2.06%)
Day range$2.86 – $3.04
Volume24,401
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.95M
Price / earnings
—
Price / book
0.14×
Price / sales
3.02×
EV / sales
-5.95×
EV / EBITDA
0.5×
Profitability
Earnings per share
-$15.22
Return on assets
-62.07%
Return on equity
-75.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
2.21×
Quick ratio
2.14×
Cash ratio
2.02×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.31M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ONCO, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$17.12K
$21.46K
$303.6K
$303.65K
$106.49K
$101.63K
$711.98K
$406.86K
Cost of revenue
$12.82K
$23.11K
$55.91K
$34.76K
$35.99K
$55.8K
$52.01K
$301.45K
Gross profit
$4.3K
-$1.66K
$247.68K
$268.89K
$70.5K
$45.83K
$659.97K
$105.41K
Selling, general and administrative
$2.25M
$2.04M
$1.5M
$2.34M
$1.52M
$1.67M
$2.63M
$2.64M
Research and development
$3.44K
$50.82K
$24.29K
-$3.21K
-$111.67K
$24.46K
-$290
$109.37K
Total operating expenses
$2.74M
$10.22M
$1.53M
$2.34M
$2.01M
$12.62M
$29.81M
$2.75M
Operating income
-$2.73M
-$10.23M
-$1.28M
-$2.07M
-$1.94M
-$12.57M
-$29.15M
-$2.65M
Interest expense
-$4.39K
-$2.24K
-$4.25K
-$300.07K
-$223.1K
-$223.59K
-$248.35K
-$384.96K
Income before taxes
-$2.87M
-$4.21M
$5.67M
-$8.78M
-$2.37M
-$8.55M
-$30.36M
-$3.88M
Income taxes
$0
$0
$525
$0
$0
$0
-$918K
-$56.38K
Net income
-$2.87M
-$4.21M
$5.67M
-$8.78M
-$2.37M
-$8.55M
-$29.44M
-$3.83M
Net income attributable to common shareholders
-$2.87M
-$4.21M
$5.67M
-$8.78M
-$2.7M
-$9.72M
-$29.64M
-$3.83M
EBITDA
-$2.24M
-$2.09M
-$1.28M
-$2.07M
-$1.34M
-$1.65M
-$1.85M
-$2.44M
Basic earnings per share
-$12.80
-$671.00
$1,812.72
-$3,125.00
-$2,379.10
-$22,725.00
-$147,053.19
-$124,540.00
Diluted earnings per share
-$12.80
-$671.00
$1,812.72
-$3,125.00
-$2,379.10
-$22,725.00
-$147,053.19
-$124,540.00
Recent news
Company coverage with links to the original publishers.
Onconetix announced that Realbotix, its pending acquisition target, has partnered with Bloom Procurement Services to launch a pilot program deploying socially assistive humanoid robots in UK care settings to address loneliness among elderly residents. Realbotix has been accredited as a supplier on Bloom's public sector marketplace. The acquisition is expected to close in the second half of 2026, subject to shareholder approval and regulatory clearances.
Onconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. However, the stock has dropped 99.11% over the past 12 months and currently trades at its annual low.
Onconetix shares surged 71.74% in premarket trading on Friday following the announcement of its acquisition of Realbotix, a company specializing in AI-driven humanoid robots. The acquisition is expected to enhance Onconetix's capabilities in AI and robotics. Additionally, the company implemented a 1-for-5 reverse stock split effective March 25. Despite the positive premarket movement, the stock remains down 92.97% over the past 12 months and trades near its 52-week low.
Onconetix and Ocuvex Therapeutics have signed a definitive merger agreement where Onconetix will acquire Ocuvex, with Ocuvex shareholders receiving 90% of the combined company's equity. The transaction is expected to close in Q4 and aims to bring ophthalmic therapeutic assets to the public markets.
Tellurian Inc. shares rose sharply after Woodside Energy announced plans to acquire the company for $900 million. Several other stocks also saw significant pre-market movement, both positive and negative.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.